Question 1

What is cannabis and how does it differ from hemp?

Accepted Answer

Cannabis is a genus of flowering plants in the family Cannabaceae that includes Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Both "cannabis" (commonly called marijuana) and hemp are the same plant species — the legal distinction is based entirely on THC content. Under the 2018 U.S. Farm Bill, hemp is defined as Cannabis sativa L. with a delta-9-THC concentration of 0.3% or less on a dry weight basis. Plants exceeding this threshold are classified as marijuana under the Controlled Substances Act and remain federally illegal. Hemp has been cultivated for thousands of years for fiber, seeds, and food. Modern hemp cultivation focuses heavily on CBD production. Cannabis grown for recreational or medical use is selectively bred for higher THC concentrations, typically ranging from 15–30% in commercial flower.

Question 2

How does cannabis affect the body?

Accepted Answer

Cannabis exerts its effects primarily through the endocannabinoid system (ECS) — a complex cell-signaling network present throughout the human body. The ECS consists of endocannabinoids (naturally produced by the body), cannabinoid receptors (CB1 and CB2), and enzymes that synthesize and break down endocannabinoids. CB1 receptors are concentrated in the brain and central nervous system, particularly in areas governing memory, pain, mood, and motor control. CB2 receptors are found primarily in immune tissues and peripheral organs. THC binds directly to CB1 receptors, producing psychoactive effects. CBD does not bind strongly to either receptor but modulates the ECS through indirect mechanisms. Beyond the ECS, cannabinoids also interact with serotonin receptors (5-HT1A), vanilloid receptors (TRPV1), GPR55, and nuclear receptors (PPARγ) — explaining the broad range of physiological effects reported.

Question 3

What is the difference between indica, sativa, and hybrid strains?

Accepted Answer

The indica/sativa/hybrid classification is a popular retail framework, but it has limited scientific validity as a predictor of effects. Botanically, these terms describe plant morphology: Cannabis indica plants are shorter and bushier; Cannabis sativa plants are taller with narrower leaves. The effects of a given cannabis product are determined primarily by its cannabinoid profile (THC, CBD, CBG, etc.) and terpene composition — not by whether it is labeled indica or sativa. A 2018 study in PLOS ONE found that the chemical profiles of commercially labeled indica and sativa strains overlapped substantially, with no reliable chemical distinction between the categories. The "indica = sedating, sativa = energizing" heuristic persists in consumer culture but is not supported by controlled research. Terpenes like myrcene, linalool, and caryophyllene likely contribute more meaningfully to the sedating or stimulating character of a product than the indica/sativa label.

Question 4

What is the endocannabinoid system?

Accepted Answer

The endocannabinoid system (ECS) is a biological signaling network discovered in the early 1990s during research into how THC affects the brain. It is now understood to be one of the most widespread receptor systems in the human body, playing a central role in maintaining homeostasis — the body's internal balance. The ECS has three core components: (1) endocannabinoids — lipid-based neurotransmitters produced on demand by the body, primarily anandamide (AEA) and 2-arachidonoylglycerol (2-AG); (2) cannabinoid receptors CB1 and CB2; and (3) metabolic enzymes (FAAH and MAGL) that break down endocannabinoids after use. The ECS regulates a remarkable range of functions including pain perception, mood, memory, appetite, sleep, immune response, and inflammation. Unlike most neurotransmitter systems, endocannabinoids are released postsynaptically and travel backward across synapses to modulate presynaptic neuron activity — a process called retrograde signaling.

Question 5

What is the difference between CBD and THC?

Accepted Answer

CBD (cannabidiol) and THC (delta-9-tetrahydrocannabinol) are the two most abundant and well-studied cannabinoids in cannabis. Despite sharing the same molecular formula (C₂₁H₃₀O₂), a single structural difference — the arrangement of a hydroxyl group — produces dramatically different pharmacological profiles. THC is a partial agonist at CB1 receptors, producing the characteristic psychoactive "high" associated with cannabis. It is responsible for euphoria, altered time perception, increased appetite, and at high doses, anxiety or paranoia. THC has FDA-approved pharmaceutical derivatives (dronabinol, nabilone) for chemotherapy-induced nausea and AIDS-related anorexia. CBD does not bind strongly to CB1 receptors and is non-psychoactive. It modulates the ECS indirectly and acts on multiple other receptor systems including 5-HT1A, TRPV1, and GPR55. CBD has one FDA-approved indication: Epidiolex for treatment-resistant epilepsy (Dravet syndrome and Lennox-Gastaut syndrome). CBD also inhibits the CYP450 enzyme system, creating clinically significant drug interactions.

Question 6

What are CBDA and THCA, and why do they matter?

Accepted Answer

CBDA (cannabidiolic acid) and THCA (tetrahydrocannabinolic acid) are the acidic precursor forms of CBD and THC, respectively. In living cannabis plants, these acidic forms are the dominant cannabinoids — CBD and THC themselves are present only in trace amounts until the plant material is heated (decarboxylated). Decarboxylation occurs when cannabis is smoked, vaporized, or cooked, converting CBDA → CBD and THCA → THC. This is why raw cannabis does not produce intoxication when consumed cold. Both acidic forms have distinct pharmacological profiles from their decarboxylated counterparts. CBDA is a potent 5-HT1A serotonin receptor agonist — approximately 100 times more potent than CBD — with promising anti-nausea and anxiolytic effects in preclinical studies. THCA is a PPARγ agonist with neuroprotective and anti-inflammatory properties, and does not bind CB1 receptors meaningfully in its native form. "THCA flower" products sold in some markets can produce intoxication when smoked because heat converts THCA to THC — a significant consumer safety consideration.

Question 7

Is Delta-8 THC safe? How does it differ from regular THC?

Accepted Answer

Delta-8-THC is a structural isomer of Delta-9-THC (the "regular" THC in cannabis) with the double bond at the 8th rather than 9th carbon position. It binds CB1 receptors with approximately 50–66% of the potency of Delta-9-THC, producing milder psychoactive effects that users often describe as less anxiety-provoking. The primary safety concern with commercial Delta-8 products is not Delta-8 itself, but the synthesis process. Delta-8 occurs naturally in cannabis at less than 1% — too low for practical extraction. Commercial products are almost entirely synthesized from CBD via acid-catalyzed isomerization. This process can produce numerous byproducts including Delta-9-THC, Delta-10-THC, and unknown reaction products. A 2021 analysis found that 100% of tested commercial Delta-8 products contained detectable Delta-9-THC, and many contained potentially harmful synthesis byproducts. The FDA has received thousands of adverse event reports related to Delta-8 products, including hospitalizations. The DEA's 2020 Interim Final Rule classifies synthetically derived THC isomers as Schedule I. Multiple states have banned Delta-8. If you choose to use Delta-8 products, only purchase those with comprehensive third-party COA testing from ISO-accredited laboratories.

Question 8

What is the entourage effect?

Accepted Answer

The entourage effect is the hypothesis that the therapeutic effects of cannabis are greater when multiple cannabinoids and terpenes work together than when isolated compounds are used alone. The term was coined by Israeli researchers Raphael Mechoulam and Shimon Ben-Shabat in 1998 and popularized by Ethan Russo in a 2011 British Journal of Pharmacology paper. The concept suggests that CBD, THC, minor cannabinoids (CBG, CBN, CBC), and terpenes (myrcene, linalool, caryophyllene) interact synergistically — modulating each other's effects and potentially improving therapeutic outcomes while reducing side effects. For example, CBD may attenuate THC-induced anxiety and cognitive impairment. The scientific evidence for the entourage effect is promising but not conclusive. Most supporting data comes from preclinical studies and observational research. A 2020 systematic review in the British Journal of Pharmacology found some evidence for synergistic effects but noted that rigorous human RCTs are lacking. The FDA's approval of Epidiolex (pure CBD isolate) demonstrates that isolated cannabinoids can be clinically effective without the full plant matrix.

Question 9

Is cannabis addictive?

Accepted Answer

Cannabis use disorder (CUD) is a recognized clinical condition in the DSM-5. Approximately 9% of people who use cannabis will develop dependence — a rate lower than alcohol (15%), nicotine (32%), or heroin (23%), but not zero. Among daily users, the rate rises to approximately 25–50%. Cannabis use disorder is characterized by tolerance (needing more to achieve the same effect), withdrawal symptoms upon cessation (irritability, sleep disturbance, appetite changes, anxiety — typically lasting 1–2 weeks), and continued use despite negative consequences. Risk factors for developing CUD include early onset of use (adolescent brain development is particularly vulnerable), frequency of use, potency of product (high-THC products carry higher risk), and genetic predisposition. CBD does not appear to be addictive and may actually have potential as a treatment for substance use disorders. If you are concerned about cannabis use, the SAMHSA National Helpline (1-800-662-4357) provides free, confidential support.

Question 10

What are the mental health risks of cannabis use?

Accepted Answer

The relationship between cannabis and mental health is complex and depends heavily on frequency of use, age of onset, THC potency, and individual genetic vulnerability. The most well-established risk is the association between heavy, early-onset cannabis use and psychosis. A 2019 Lancet Psychiatry study found that daily use of high-potency cannabis (>10% THC) was associated with a 5-fold increased risk of psychotic disorder compared to never-users. Individuals with a personal or family history of psychosis or schizophrenia should avoid cannabis use. Cannabis can also worsen anxiety and depression in some users, particularly at high doses or with high-THC products. Paradoxically, low-dose CBD and balanced THC:CBD products may have anxiolytic effects — the dose and ratio matter significantly. Adolescent use is of particular concern: the brain continues developing until approximately age 25, and regular cannabis use during adolescence is associated with cognitive impairment, reduced educational attainment, and increased risk of developing psychiatric disorders.

Question 11

Does cannabis interact with medications?

Accepted Answer

Yes — cannabis and cannabinoids have clinically significant drug interactions that are frequently underappreciated. The primary mechanism is inhibition of the CYP450 enzyme system, particularly CYP3A4 and CYP2C9, which metabolize a large proportion of commonly prescribed medications. CBD is a potent inhibitor of CYP2C19 and CYP3A4. This can increase blood levels of medications metabolized by these enzymes — including warfarin (anticoagulant), clobazam (antiepileptic), tacrolimus (immunosuppressant), and many others — potentially to toxic levels. The FDA-approved Epidiolex label carries a warning about this interaction. THC can potentiate CNS depressants (opioids, benzodiazepines, alcohol) and may cause additive tachycardia with stimulants or anticholinergic medications. Both THC and CBD can affect blood pressure and heart rate. Patients taking any prescription medications — especially anticoagulants, antiepileptics, immunosuppressants, or psychiatric medications — should consult their healthcare provider before using cannabis products.

Question 12

Is cannabis safe during pregnancy or breastfeeding?

Accepted Answer

No. Major medical organizations — including the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics (AAP), and the CDC — advise against any cannabis use during pregnancy and breastfeeding. THC crosses the placenta and accumulates in fetal tissue. Studies have associated prenatal cannabis exposure with lower birth weight, preterm birth, stillbirth, and neurodevelopmental effects including impaired executive function, attention, and memory in children. A 2020 JAMA Pediatrics study found that prenatal cannabis exposure was associated with increased risk of psychopathology in offspring at age 9–10. THC is also present in breast milk and can be detected for up to 6 days after use. The developing infant brain is particularly vulnerable to cannabinoid exposure. The common misconception that cannabis is "natural" and therefore safe during pregnancy is not supported by evidence. If you are pregnant or breastfeeding and using cannabis for nausea or pain, discuss safer alternatives with your healthcare provider.

Question 13

Does cannabis impair driving?

Accepted Answer

Yes. Cannabis impairs driving ability, and driving under the influence of cannabis is illegal in all U.S. states. THC impairs reaction time, divided attention, lane tracking, and speed regulation. A 2021 meta-analysis in JAMA Internal Medicine found that cannabis use approximately doubled the risk of motor vehicle crashes. The degree of impairment varies with dose, tolerance, route of administration, and individual factors. Impairment typically peaks 20–40 minutes after smoking and can persist for 2–4 hours. Edibles produce delayed onset (30–90 minutes) but longer duration of impairment (4–8 hours or more), creating a particular risk for users who misjudge their level of intoxication. Unlike alcohol, there is no validated roadside test for cannabis impairment. Blood THC levels do not reliably correlate with impairment — experienced users may have high blood THC with minimal impairment, while infrequent users may be significantly impaired at lower levels. Law enforcement increasingly uses standardized field sobriety tests and drug recognition expert evaluations. CBD alone does not impair driving at typical doses. However, products containing both CBD and THC carry impairment risk proportional to their THC content.

Question 14

Is cannabis legal federally in the United States?

Accepted Answer

No. Cannabis (marijuana) remains a Schedule I controlled substance under the federal Controlled Substances Act (CSA), meaning the federal government classifies it as having no accepted medical use and a high potential for abuse. This classification has been in place since 1970. In May 2024, the DEA proposed rescheduling cannabis from Schedule I to Schedule III — a historic shift that would acknowledge its medical utility and reduce federal penalties. However, rescheduling to Schedule III would not legalize recreational use or resolve the conflict between state and federal law. As of 2025, the rescheduling process remains ongoing. Hemp (cannabis with ≤0.3% THC) was federally legalized under the 2018 Farm Bill, which is why CBD products derived from hemp are widely available. The FDA retains authority over hemp-derived CBD in food and dietary supplements and has not approved CBD as a food additive. The conflict between state and federal law creates significant complexity for cannabis businesses, banking, taxation (Section 280E), and interstate commerce.

Question 15

Which states have legalized cannabis?

Accepted Answer

As of 2025, 24 states plus Washington D.C. have legalized recreational cannabis for adults 21 and older. An additional 14 states have comprehensive medical cannabis programs. Only a small number of states maintain complete prohibition. States with recreational legalization include: Alaska, Arizona, California, Colorado, Connecticut, Delaware, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oregon, Rhode Island, Vermont, Virginia, Washington, and Washington D.C. State laws vary significantly in areas including: possession limits, home cultivation rights, retail licensing, consumption locations, expungement of prior convictions, social equity provisions, and product testing requirements. Even in legal states, federal law still applies on federal lands (national parks, military bases), in federal buildings, and for federally regulated activities (commercial aviation, federal employment). Transporting cannabis across state lines remains a federal crime regardless of the legal status in both states.

Question 16

How do I get a medical cannabis card?

Accepted Answer

Medical cannabis programs are administered at the state level, and requirements vary significantly. The general process involves: (1) confirming your state has a medical cannabis program and that your condition qualifies; (2) obtaining a physician certification from a licensed healthcare provider; (3) registering with your state's medical cannabis program and paying applicable fees; and (4) receiving your medical cannabis card. Qualifying conditions vary by state but commonly include: cancer, HIV/AIDS, multiple sclerosis, epilepsy, PTSD, chronic pain, Crohn's disease, glaucoma, and terminal illness. Some states have open-ended provisions allowing physicians to certify any condition they believe may benefit from cannabis. Telehealth services have made physician certifications more accessible in many states. Costs typically range from $50–$200 for the physician visit plus $25–$100 for state registration fees. Benefits of a medical card over recreational purchase (where both are available) may include: lower taxes, higher possession limits, access to higher-potency products, ability to purchase at younger ages (18 vs. 21 in some states), and legal protections in some employment contexts.

Question 17

How do I read a Certificate of Analysis (COA)?

Accepted Answer

A Certificate of Analysis (COA) is a third-party laboratory report that verifies the cannabinoid content and safety profile of a cannabis or hemp product. Understanding how to read a COA is essential for making informed purchasing decisions. Key sections to review: (1) Cannabinoid panel — lists concentrations of CBD, THC, and other cannabinoids. Verify the THC content matches the label claim and complies with legal limits. (2) Terpene panel (if included) — identifies aromatic compounds that contribute to effects and flavor. (3) Pesticide screening — confirms the product is free from agricultural chemicals. Look for "pass" on all analytes. (4) Heavy metals — tests for lead, arsenic, cadmium, and mercury. All should be below action limits. (5) Residual solvents — relevant for extracts; confirms no harmful extraction solvents remain. (6) Microbials — tests for harmful bacteria, mold, and yeast. Critical verification steps: Confirm the lab is ISO 17025-accredited. Check that the batch number on the COA matches your product. Verify the test date is recent (within 12 months for shelf-stable products). Be wary of COAs from labs with financial relationships to the brand being tested.

Question 18

What is the difference between full-spectrum, broad-spectrum, and CBD isolate?

Accepted Answer

These terms describe how much of the cannabis plant's chemical profile is retained in a CBD product: Full-spectrum extracts contain all naturally occurring cannabinoids (including up to 0.3% THC in hemp-derived products), terpenes, flavonoids, and other plant compounds. Proponents argue this preserves the entourage effect. Full-spectrum products will contain trace THC and may cause a positive drug test result. Broad-spectrum extracts retain most cannabinoids and terpenes but have THC removed (typically to non-detectable levels). This aims to provide entourage effect benefits without THC exposure. However, THC removal processes can also remove other beneficial compounds, and "THC-free" claims should be verified by COA. CBD isolate is pure CBD — typically 99%+ purity with all other plant compounds removed. It is odorless, tasteless, and contains no THC. Isolate is preferred for precise dosing, drug-tested individuals, and those sensitive to other cannabinoids. Some research suggests isolate may require higher doses than full-spectrum to achieve equivalent effects. The "best" option depends on your goals, sensitivity to THC, drug testing requirements, and the specific condition being addressed.

Question 19

How do I dose CBD? Is there a standard dose?

Accepted Answer

There is no universal standard CBD dose — effective doses vary widely based on the condition being addressed, individual body weight and metabolism, the product's bioavailability, and individual sensitivity. The FDA has only established a dose for one CBD product: Epidiolex, which is dosed at 2.5–10mg/kg/day for epilepsy. For general wellness use, the "start low, go slow" principle is widely recommended. A common starting approach: begin with 10–20mg per day, assess effects over 1–2 weeks, and increase by 5–10mg increments if needed. Most consumer studies have used doses ranging from 25–150mg/day for anxiety and sleep. Bioavailability varies significantly by route: sublingual tinctures (15–35% bioavailability), oral capsules/edibles (6–19%), inhalation (31–56%), and topicals (minimal systemic absorption). This means the same labeled dose delivers very different amounts of CBD to the bloodstream depending on the product type. Important: CBD inhibits CYP450 enzymes and can interact with medications. Anyone taking prescription medications should consult a healthcare provider before starting CBD. The FDA has not approved CBD as a dietary supplement, and quality control in the unregulated market varies enormously.

Question 20

How is cannabis research evidence graded?

Accepted Answer

Cannabis research is evaluated using the same evidence hierarchy applied to all medical interventions. From strongest to weakest: (1) Systematic reviews and meta-analyses of multiple randomized controlled trials (RCTs); (2) Individual well-designed RCTs; (3) Cohort and case-control studies; (4) Case series and case reports; (5) Expert opinion and preclinical (animal/cell) data. On this site, we use a simplified three-tier grading system: Grade A (strong evidence) — supported by multiple RCTs or FDA approval; Grade B (moderate evidence) — supported by some RCTs or systematic reviews; Grade C (preliminary evidence) — preclinical or observational data only. A critical challenge in cannabis research is that Schedule I classification in the U.S. has historically made it extremely difficult to conduct FDA-compliant clinical trials. Researchers faced barriers including limited access to research-grade cannabis, DEA licensing requirements, and funding restrictions. This has created a situation where a widely used substance has a relatively thin clinical evidence base compared to pharmaceutical drugs with similar usage rates. The research landscape is improving: the DEA's proposed rescheduling to Schedule III would significantly ease research barriers, and several large-scale trials are currently underway.

Question 21

Can cannabis treat cancer?

Accepted Answer

This is one of the most important distinctions in cannabis medicine: there is a significant difference between cannabis managing cancer-related symptoms and cannabis treating cancer itself. For symptom management, the evidence is reasonably strong. FDA-approved cannabinoid medications (dronabinol, nabilone) are established treatments for chemotherapy-induced nausea and vomiting. Cannabis also has evidence for cancer-related pain, appetite stimulation, and sleep disturbance. For direct anti-tumor effects, the picture is very different. Numerous preclinical studies (cell cultures and animal models) have shown that cannabinoids can inhibit tumor growth, induce apoptosis (programmed cell death), and reduce angiogenesis (tumor blood supply). These findings generated significant excitement. However, preclinical results have not translated to proven anti-cancer treatments in humans. No clinical trial has demonstrated that cannabis or cannabinoids can cure, treat, or meaningfully slow the progression of any cancer in humans. Patients should be cautious about claims that cannabis "cures cancer." Using cannabis as a substitute for evidence-based cancer treatment can cause serious harm. Cannabis may be a valuable adjunct for symptom management alongside conventional treatment, but it is not a replacement for it.

Question 22

Is CBD FDA-approved?

Accepted Answer

One CBD product is FDA-approved: Epidiolex (cannabidiol oral solution), approved in June 2018 for treatment of seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients 1 year of age and older. Epidiolex is a pharmaceutical-grade, highly purified CBD product manufactured under strict quality controls. The FDA has not approved CBD as a dietary supplement, food additive, or over-the-counter drug. The FDA's position is that because CBD was first approved as a drug (Epidiolex), it cannot legally be marketed as a dietary supplement under current law — a regulatory framework that has created significant tension with the booming CBD consumer market. The FDA has issued warning letters to companies making unsubstantiated health claims about CBD products and has expressed concern about the lack of safety data for long-term CBD use, particularly at high doses. In 2023, the FDA announced it would not pursue a regulatory pathway for CBD as a dietary supplement and called on Congress to create a new regulatory framework. This means the vast majority of CBD products on the market exist in a regulatory gray area — they are widely sold but not formally approved or regulated as drugs or supplements.

Common Cannabis Questions, Answered